EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...
/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...
/CNW/ - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by...
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...
Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.